Comparative Pharmacology
Head-to-head clinical analysis: DASETTA 1 35 versus TRI LEGEST FE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DASETTA 1 35 versus TRI LEGEST FE.
DASETTA 1/35 vs TRI-LEGEST FE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of an estrogen (ethinyl estradiol) and a progestin (norethindrone). Suppresses gonadotropin-releasing hormone (GnRH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion from the pituitary, thereby inhibiting ovulation. Additionally, induces changes in cervical mucus (impenetrability to sperm) and endometrium (reduced likelihood of implantation).
Tri-Legest FE is a combination oral contraceptive containing ethinyl estradiol and norethindrone acetate. It prevents ovulation by inhibiting gonadotropin release (FSH and LH) and alters cervical mucus and endometrial lining to impede sperm penetration and implantation.
One tablet orally once daily, each containing 1 mg norethindrone acetate and 35 mcg ethinyl estradiol.
One tablet orally once daily for 28-day cycle: 21 days active tablets (norethindrone/ethinyl estradiol) followed by 7 days placebo. For contraception only.
None Documented
None Documented
Norethindrone: 5-14 hours (mean 8 hours); ethinyl estradiol: 10-20 hours (mean 14 hours). Clinical context: steady-state achieved within 5-7 days.
Norethindrone: 7-8 hours; Ethinyl estradiol: 18 hours (terminal). Steady-state reached after 7 days; clinical contraceptive efficacy requires consistent dosing.
Renal (55-60% as metabolites, 25-30% as unchanged drug and conjugates), biliary/fecal (30-35% as metabolites).
Renal: ~60% (metabolites), Fecal: ~30% (metabolites), Biliary: minor (~5% as conjugates)
Category C
Category C
Oral Contraceptive
Oral Contraceptive